Search hospitals

>

Mississippi

>

Jackson

University Of Mississippi Medical Center

Claim this profile

Jackson, Mississippi 39216

Global Leader in Cancer

Global Leader in Leukemia

Conducts research for Brain Tumor

Conducts research for Lung Cancer

Conducts research for Ovarian Cancer

1030 reported clinical trials

45 medical researchers

Photo of University Of Mississippi Medical Center in JacksonPhoto of University Of Mississippi Medical Center in JacksonPhoto of University Of Mississippi Medical Center in Jackson

Summary

University Of Mississippi Medical Center is a medical facility located in Jackson, Mississippi. This center is recognized for care of Cancer, Leukemia, Brain Tumor, Lung Cancer, Ovarian Cancer and other specialties. University Of Mississippi Medical Center is involved with conducting 1,030 clinical trials across 1,197 conditions. There are 45 research doctors associated with this hospital, such as Anderson (Andy) B. Collier, Betty L. Herrington, John C. Henegan, and Dennis P. Morgan.

Area of expertise

1

Cancer

Global Leader

University Of Mississippi Medical Center has run 77 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Leukemia

Global Leader

University Of Mississippi Medical Center has run 67 trials for Leukemia. Some of their research focus areas include:

NTRK1 positive
NTRK positive
ABL-class fusions positive

Top PIs

Clinical Trials running at University Of Mississippi Medical Center

Bladder Cancer

Prostate Cancer

Bladder Carcinoma

Kidney Cancer

Testicular cancer

Breast cancer

Lung Cancer

Leukemia

Neuroblastoma

Acute Lymphoblastic Leukemia

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.

Recruiting

2 awards

Phase 3

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University Of Mississippi Medical Center?

Where is University Of Mississippi Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University Of Mississippi Medical Center accept?

What awards or recognition has University Of Mississippi Medical Center received?